Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › Safety and efficacy of combined clozapine–lithium pharmacotherapy

Publikation

Safety and efficacy of combined clozapine–lithium pharmacotherapy

Bender, Stefan; Linka, Thomas; Wolstein, Jörg; u. a. (2004): Safety and efficacy of combined clozapine–lithium pharmacotherapy, in: The international journal of neuropsychopharmacology : official scientific journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), Cambridge: Univ. Press, Jg. 7, Nr. 1, S. 59–63, doi: 10.1017/S1461145703003870.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Bender, Stefan
Linka, Thomas
Gehendges, Susanne
Paulus, Hermann-Josef
Schall, Ulrich
Gastpar, Markus
Titel der Zeitschrift
The international journal of neuropsychopharmacology : official scientific journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP)
ISSN
1461-1457
Verlagsangabe
Univ. Press : Cambridge
Erscheinungsjahr
2004
Jahrgang
7
Heft
1
Sprache(n)
Englisch
DOI
Abstract

Several case reports described neurotoxic side-effects in the course of a combined clozapine-lithium treatment. Here we report on the safety and efficacy of this combination in a sample of 44 hospital patients. Medical records were retrospectively audited and a subsample of 23 patients was re-assessed. Mean total duration of combined treatment was 23.5 months. The combination (indications: prophylaxis; treatment of affective symptoms or aggression/excitement; augmentation of neuroleptic efficacy) was rated effective in 84% and adverse events were reported in 64% of the patients. Notably, most of the adverse events were benign and transient. However, 8 patients (18%) developed transient neurological adverse events that were genuinely novel in only 3 patients (7%) and coincided with high dosage of medication or high plasma levels or serotonergic (antidepressant) co-medication. Our data suggest that combined clozapine-lithium treatment may appear to be safe and effective when administered within a moderate therapeutic dose range and without serotonergic co-medication or other substances interfering with clozapine metabolism.

Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
09.11.2018, 09.11.2018

Permalink: https://fis.uni-bamberg.de/handle/uniba/44667 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 15.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.